Efficacy and safety of rebamipide tablets combined with rabeprazole sodium enteric-coated tablets in the treatment of chronic atrophic gastritis

Central Plains Medical Journal Pub Date : 2020-02-25 DOI:10.3760/CMA.J.ISSN.1674-4756.2020.04.031

Y. Xue, Jing Li, Yunfeng Hou

{"title":"Efficacy and safety of rebamipide tablets combined with rabeprazole sodium enteric-coated tablets in the treatment of chronic atrophic gastritis","authors":"Y. Xue, Jing Li, Yunfeng Hou","doi":"10.3760/CMA.J.ISSN.1674-4756.2020.04.031","DOIUrl":null,"url":null,"abstract":"Objective \nTo analyze the efficacy and safety of rebamipide tablets combined with rabeprazole sodium enteric-coated tablets in the treatment of chronic atrophic gastritis (CAG). \n \n \nMethods \nA total of 192 CAG patients admitted to Central Hospital of Henan Energy Jiaozuo Coal Industry Group from January 2013 to January 2018 were included and randomly divided into control group and observation group according to the ratio of 1∶1, with 96 cases in each group. Control group was treated with rabeprazole sodium enteric-coated tablets, and observation group was given rebamipide tablets + rabeprazole sodium enteric-coated tablets, and they were treated for 4 weeks. The clinical efficacy, pathological scores (gland atrophy, intestinal metaplasia, dysplasia), gastric function-related indicators, including gastrin-17 (GAS-17), pepsinogen I (PGI), epidermal growth factor (EGF), endothelin-1 (ET-1), Hp eradication rate and safety were compared between the two groups. \n \n \nResults \nAfter treatment, the total improvement rate of treatment and negative conversion rate of Hp in observation group were significantly higher than those in control group, (91.67% and 80.21%) vs. (78.12% and 62.50%), the difference was statistically significant (P 0.05), with good safety. \n \n \nConclusions \nRebamipide tablets combined with rabeprazole sodium enteric-coated tablets has obvious effects on CAG, and it can effectively alleviate the clinical symptoms of patients and regulate the levels of gastric function-related indicators, with good safety. \n \n \nKey words: \nRebamipide tablets; Rabeprazole sodium enteric-coated tablets; Chronic atrophic gastritis","PeriodicalId":9667,"journal":{"name":"Central Plains Medical Journal","volume":"8 1","pages":"100-103"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central Plains Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1674-4756.2020.04.031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To analyze the efficacy and safety of rebamipide tablets combined with rabeprazole sodium enteric-coated tablets in the treatment of chronic atrophic gastritis (CAG). Methods A total of 192 CAG patients admitted to Central Hospital of Henan Energy Jiaozuo Coal Industry Group from January 2013 to January 2018 were included and randomly divided into control group and observation group according to the ratio of 1∶1, with 96 cases in each group. Control group was treated with rabeprazole sodium enteric-coated tablets, and observation group was given rebamipide tablets + rabeprazole sodium enteric-coated tablets, and they were treated for 4 weeks. The clinical efficacy, pathological scores (gland atrophy, intestinal metaplasia, dysplasia), gastric function-related indicators, including gastrin-17 (GAS-17), pepsinogen I (PGI), epidermal growth factor (EGF), endothelin-1 (ET-1), Hp eradication rate and safety were compared between the two groups. Results After treatment, the total improvement rate of treatment and negative conversion rate of Hp in observation group were significantly higher than those in control group, (91.67% and 80.21%) vs. (78.12% and 62.50%), the difference was statistically significant (P 0.05), with good safety. Conclusions Rebamipide tablets combined with rabeprazole sodium enteric-coated tablets has obvious effects on CAG, and it can effectively alleviate the clinical symptoms of patients and regulate the levels of gastric function-related indicators, with good safety. Key words: Rebamipide tablets; Rabeprazole sodium enteric-coated tablets; Chronic atrophic gastritis

查看原文本刊更多论文

利巴米胺片联合雷贝拉唑钠肠溶片治疗慢性萎缩性胃炎的疗效和安全性

目的分析利巴米特片联合雷别拉唑钠肠溶片治疗慢性萎缩性胃炎(CAG)的疗效和安全性。方法选取2013年1月~ 2018年1月在河南能源焦作煤业集团中心医院住院的CAG患者192例，按1∶1的比例随机分为对照组和观察组，每组96例。对照组患者给予雷贝拉唑钠肠溶片治疗，观察组患者给予雷巴米胺片+雷贝拉唑钠肠溶片，疗程4周。比较两组患者的临床疗效、病理评分(腺体萎缩、肠化生、不典型增生)、胃泌素-17 (GAS-17)、胃蛋白酶原I (PGI)、表皮生长因子(EGF)、内皮素-1 (ET-1)等胃功能相关指标、Hp根除率及安全性。结果治疗后，观察组患者治疗总改善率和Hp阴性转换率均显著高于对照组，分别为(91.67%、80.21%)和(78.12%、62.50%)，差异有统计学意义(P 0.05)，且安全性较好。结论利巴米特片联合雷贝拉唑钠肠溶片治疗CAG效果明显，可有效缓解患者临床症状，调节胃功能相关指标水平，且安全性较好。关键词:利巴米胺片;雷贝拉唑钠肠溶片;慢性萎缩性胃炎

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Central Plains Medical Journal

自引率

0.00%

发文量